ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1064

Anti-SMN Autoantibodies Are Associated with Systemic Sclerosis Small Bowel Involvement in anti-U1RNP Positive Autoimmune Myositis

Caroline Vo1, Océane Landon-Cardinal2, Alexandra Albert3, Alain Meyer4, Valérie Leclair5, Josiane Bourré-Tessier2, Sabrina Hoa2, Eric Rich1, Jean-Richard Goulet1, Benjamin Ellezam6, Maude Bouchard-Marmen7, Martial Koenig8, Geneviève Gyger5, Ira N. Targoff9, Marie Hudson5, Minoru Satoh10, Marvin Fritzler11, Yves Troyanov12 and Jean-Luc Senécal2, 1Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, 2Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 3Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada, 4Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, 5Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, 6Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada, 7Division of Rheumatology, Centre Hospitalier de l’Université Laval, Department of Medicine, Université Laval, Québec, QC, Canada, 8Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, 9University of Oklahoma Health Sciences Center, Oklahoma City, OK, 10Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, 11Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 12Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), Myopathies, Myositis, Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Muscle Biology, Myositis & Myopathies Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The survival of motor neuron (SMN)/gemin proteins are components of a multifunctional protein complex that plays an essential role in RNA metabolism. SMN is present in Cajal bodies, i.e. nuclear structures that play an essential role in the assembly of small nuclear RNPs. Deletion or mutation of the SMN gene is associated with spinal muscular atrophy. Autoantibodies (aAbs) to SMN (anti-SMN) have not been thoroughly studied. Anti-SMN have been associated with scleromyositis (SM), originally in a cohort of 163 autoimmune myositis (AIM) (n=3, 1.8%) patients, and recently in a cohort of 20 seronegative SM (n=5, 25%). In another report, a single patient with anti-U1RNP and anti-SMN aAbs had a necrotizing autoimmune myopathy. The aim of this study was to evaluate the prevalence of anti-SMN aAbs in patients with anti-U1RNP+ AIM, and compare phenotypic differences in patients with and without anti-SMN aAbs.

Methods: All patients with a diagnosis of AIM associated with anti-U1RNP were identified from a clinically and serologically described retrospective cohort of 100 AIM patients. Sera were analyzed for anti-SMN by addressable laser bead immunoassay with results expressed as median fluorescence units (MFU) and positivity defined as 3 SD above the mean of normal and unrelated disease controls ( >900 MFU), as previously validated by protein A-assisted immunoprecipitation. Clinical features were collected to assess the presence of ACR/EULAR and non ACR/EULAR features of systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and Sjögren syndrome (SS).

Results: Of 9 AIM patients with anti-U1RNP+, 8 (88.9%) were females and median age at myositis diagnosis was 45 years old (range 24–61). At presentation, clinical features included Raynaud phenomenon (100% of patients), sclerodactyly (100%), lower esophageal dysmotility (88%), arthritis (78%) and proximal weakness (100%). Mean serum CK level was 2601 IU/L (range 329–6000). At myositis diagnosis, 88%, 22% and 22% of 9 patients fulfilled the ACR/EULAR criteria for SSc, SLE and SS, respectively. Five of 9 patients (55.6%) had anti-SMN aAbs (median 15952 MFU, range 4321–18848). These patients had a higher proportion of neck flexor weakness (60% vs 0%), bilateral trigeminal neuropathy (40% vs 25%), interstitial lung disease (40% vs 0%), acute lupus rash (80% vs 25%) and leucopenia (80% vs 25%) compared to patients without anti-SMN aAbs. Strikingly, only patients with anti-SMN aAbs had SSc small-bowel involvement (n=4/5, 80% vs n=0/4, 0%, P=0.048 by Fisher’s exact test) that included pneumatosis intestinalis (n=2/4), small intestine bacterial overgrowth (n=3/4) and pseudo-obstruction (n=4/4). One of these patients required parenteral nutrition whereas 3 others presented severe pseudo-obstruction necessitating hospitalization. At last follow-up (mean duration 12 years), 100%, 22% and 67% of 9 patients fulfilled the ACR/EULAR criteria for SSc, SLE and SS, respectively.

Conclusion: More than 50% of patients with anti-U1RNP+ AIM and SSc also have high titers of anti-SMN aAbs. The presence of anti-SMN aAbs may be predictive of severe SSc small bowel involvement compared to patients without anti-SMN aAbs.


Disclosure: C. Vo, None; O. Landon-Cardinal, None; A. Albert, None; A. Meyer, None; V. Leclair, None; J. Bourré-Tessier, None; S. Hoa, None; E. Rich, None; J. Goulet, None; B. Ellezam, None; M. Bouchard-Marmen, None; M. Koenig, None; G. Gyger, None; I. Targoff, None; M. Hudson, None; M. Satoh, None; M. Fritzler, Inova Diagnostics Inc, 5, 8, Werfen International, 5, 8; Y. Troyanov, None; J. Senécal, None.

To cite this abstract in AMA style:

Vo C, Landon-Cardinal O, Albert A, Meyer A, Leclair V, Bourré-Tessier J, Hoa S, Rich E, Goulet J, Ellezam B, Bouchard-Marmen M, Koenig M, Gyger G, Targoff I, Hudson M, Satoh M, Fritzler M, Troyanov Y, Senécal J. Anti-SMN Autoantibodies Are Associated with Systemic Sclerosis Small Bowel Involvement in anti-U1RNP Positive Autoimmune Myositis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anti-smn-autoantibodies-are-associated-with-systemic-sclerosis-small-bowel-involvement-in-anti-u1rnp-positive-autoimmune-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-smn-autoantibodies-are-associated-with-systemic-sclerosis-small-bowel-involvement-in-anti-u1rnp-positive-autoimmune-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology